6.11
0.00%
0.010
Precedente Chiudi:
$6.12
Aprire:
$6.17
Volume 24 ore:
4,699
Relative Volume:
0.01
Capitalizzazione di mercato:
$202.36M
Reddito:
-
Utile/perdita netta:
$-62.31M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-21.34%
1M Prestazione:
-41.83%
6M Prestazione:
-59.20%
1 anno Prestazione:
-44.41%
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Confronta LXEO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
LXEO | 6.065 | 202.36M | 0 | -62.31M | 0 | 0.00 |
VRTX | 447.51 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.90 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.12 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.75 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.52 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Lexeo stock hits 52-week low at $5.8 amid market challenges - Investing.com India
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Yahoo Finance
(LXEO) Trading Advice - Stock Traders Daily
FY2024 EPS Forecast for Lexeo Therapeutics Cut by Analyst - MarketBeat
FY2024 Earnings Estimate for LXEO Issued By Leerink Partnrs - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
HC Wainwright Has Negative Estimate for LXEO FY2024 Earnings - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report - TipRanks
Janus Henderson Group PLC's Strategic Acquisition in Lexeo Thera - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Lexeo Therape - GuruFocus.com
Lexeo Therapeutics Strengthens Leadership with New Board Appointment - TipRanks
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - The Manila Times
Lexeo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexeo Therapeutics Secures FDA Alignment, Reports $157M Cash Position Despite Q3 Loss | LXEO Stock News - StockTitan
Lexeo stock hits 52-week low at $7.54 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock hits 52-week low at $7.54 amid market challenges - Investing.com India
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $22.14 - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat
Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum
Lexeo reports positive Alzheimer's drug trial results - Investing.com India
Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire
How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online
Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment - MarketWatch
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to - The Bakersfield Californian
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
(LXEO) Investment Analysis - Stock Traders Daily
Novo Holdings A S Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' (LXEO) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - The Manila Times
Lexeo Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference - StockTitan
R. Nolan Townsend - Crain's New York Business
(LXEO) Proactive Strategies - Stock Traders Daily
Suppliers Pushing Novel Analytical Methods Testing Forward - BioProcess Online
Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of Stock - MarketBeat
Lexeon therapeutics CEO sells $40,495 in shares - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Long Term Trading Analysis for (LXEO) - Stock Traders Daily
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth - Investing.com India
Novo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth By Investing.com - Investing.com UK
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times
LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World
Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexeo Therapeutics Inc Azioni (LXEO) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Townsend Richard Nolan | Chief Executive Officer |
Nov 11 '24 |
Sale |
7.82 |
2,500 |
19,557 |
120,695 |
Townsend Richard Nolan | Chief Executive Officer |
Oct 10 '24 |
Option Exercise |
2.33 |
5,000 |
11,650 |
125,695 |
Townsend Richard Nolan | Chief Executive Officer |
Oct 10 '24 |
Sale |
8.10 |
5,000 |
40,496 |
120,695 |
Townsend Richard Nolan | Chief Executive Officer |
Sep 10 '24 |
Option Exercise |
2.33 |
5,000 |
11,650 |
125,695 |
Townsend Richard Nolan | Chief Executive Officer |
Sep 10 '24 |
Sale |
10.65 |
5,000 |
53,274 |
120,695 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):